|
Management of Aromatase Inhibitor (AI)-Pretreated Advanced Breast Cancer
Bachelot T et al. TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients with hormone-receptor positive, HER2 negative metastatic breast cancer with prior exposure to aromatase inhibitors. San Antonio Breast Cancer Symposium 2010; Abstract S6-1.
Burstein HJ et al. CALGB 40302: Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: A double-blinded, placebo-controlled, randomized phase III study. San Antonio Breast Cancer Symposium 2010; Abstract PD05-01.
Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
|
